| |
Before Treatment |
After Treatment |
| Base line characteristics
(Mean ± SD) |
Group 1
(n=490) |
Group 2
(n=320) |
P |
Adjusted
P value |
Group 1
(n=490) |
Group 2
(n=320) |
P |
Adjusted
P value |
| Age (years) |
58.9 ± 9.7 |
55.7 ± 9.1 |
<0.001 |
0.02 |
61.6 ± 9.0 |
58.8 ± 9.0 |
0.001 |
0.03 |
| Males/Females (%) |
225/265 (46/54) |
134/186 (42/58) |
0.9 |
- |
225/265 (46/54) |
134/186 (42/58) |
0.9 |
- |
| Time since diagnosis of T2D (yrs) |
8.2 ± 2.1 |
8.7 ± 2.9 |
0.06 |
- |
11.8 ± 2.0 |
11.6 ± 3.0 |
0.07 |
- |
| Duration of HT
(years) |
5.5 ± 3.9 |
7.8 ± 3.1 |
0.001 |
0.04 |
8.3 ± 3.6 |
10.5 ± 3.0 |
<0.001 |
0.03 |
| S.B.P. (mm Hg) |
129.20 ± 15.9 |
135.44 ± 21.1 |
0.001 |
0.02 |
126.3 ± 14.6 |
130.6 ± 20.0 |
0.09 |
0.04 |
| D.B.P. (mm Hg) |
80.5 ± 6.9 |
81.9 ± 6.0 |
0.15 |
- |
80.1 ± 4.5 |
81.0 ± 5.8 |
0.2 |
- |
| BMI (kg/m2) |
25.8 ± 4.0 |
25.6 ± 4.5 |
0.6 |
- |
24.6 ± 3.5 |
25.1 ± 4.3 |
0.7 |
- |
| HbA1c (%) |
7.1 ± 1.7 |
7.7 ± 2.1 |
0.007 |
0.03 |
4.0 ± 1.3 |
4.4 ± 2.0 |
0.009 |
0.02 |
| Hb (gm/dl) |
11.4 ± 1.6 |
10.2 ± 1.9 |
<0.001 |
0.01 |
12.0 ± 1.3 |
11.0 ± 1.3 |
0.009 |
0.01 |
| TC |
260.3 ± 63.7 |
255.3 ± 64.3 |
0.89 |
– |
171.4 ± 40.7 |
184.1 ± 60.7 |
0.14 |
– |
| TG (mg%) |
207.6 ± 38.3 |
204.9 ± 39.2 |
0.86 |
– |
164.9 ± 71.2 |
170.7 ± 96.1 |
0.9 |
- |
| HDL (mg%) |
61.1 ± 16.1 |
63.5 ± 15.1 |
0.74 |
– |
50.8 ± 14.8 |
52.6 ± 13.8 |
0.6 |
- |
| LDL-C (mg/dl) |
98.7 ± 34.9 |
100.4 ± 41.8 |
0.2 |
– |
93.0 ± 34.7 |
96.6 ± 43.9 |
0.22 |
- |
| HDL-C (mg/dl) |
47.1 ± 10.1 |
48.9 ± 20.6 |
0.38 |
– |
42.7 ± 8.3 |
43.6 ± 12.3 |
0.61 |
- |
(p<0.05 is significant) [BMI: Body Mass Index, HT: Hypertension, Hb: Hemoglobin, SBP: Systolic Blood Pressure, DBP: Diastolic Blood Pressure, T2D: Type 2 Diabetes, TC: Total Cholesterol, TG: Triglyceride, LDL-C: Low Density Lipoprotein Cholesterol, HDL-C: High Density Lipoprotein Cholesterol]. Adjusted P value is after multivariate regression analysis. Group 1; type 2 diabetes without nephropathy, Group 2; type 2 diabetes with nephropathy. |
